AVC Position Statements
|
Statements regarding the majority
opinion of the membership of the Academy of Veterinary
Consultants. The expressed views or opinions of position
statements are not binding upon any AVC member but
are suggested guidelines for the membership and industry.
Any active AVC member can submit a position statement
to the Standards of Practice Committee. The committee
can refer the statement to the Board if desired, and
the Board can dissolve it, change it and send it back
to committee, or approve it and send it on to the
membership. If presented to the general membership,
the statement must be approved by a majority of the
ballots cast. Ballots will be online for the membership,
which can include being added to a newsletter. If
approved by the membership, the statement will be
added to the Manual and listed for reference in the
annual membership directory but will not be added
to the By-Laws.
|
AMINOGLYCOSIDE
ANTIBIOTIC POSITION STATEMENT
|
The systemic use of aminoglycoside antibiotics presents
a potential conflict to the stated objectives of the
AVC Standards of Practice because scientific justification
for such use is limited, and because it is known that
identifiable residues in kidney tissue can result for
an undetermined extended period of time. Therefore,
the AVC hereby resolves that until further scientific
information becomes available alleviating safety and
efficacy concerns, aminoglycoside antibiotics should
not be used in cattle, except as specifically approved
by the FDA. |
BVD
POSITION STATEMENT
|
The beef and dairy industries suffer enormous loss
due to effects of bovine diarrhea virus (BVDV) infection.
The highly mutable nature of BVDV and the emergence
of highly virulent strains of BVDV contribute to limited
success of present control programs. Also, persistently
infected cattle are the primary source of infection
and effective testing procedures are available to identify
those infected carriers. Therefore, it is the resolve
of the Academy of Veterinary Consultants that the
beef and dairy industries adopt measures to control
and target eventual eradication of BVDV from North
America.
The AVC position statement on Bovine Viral Diarrhea (BVD) identifies persistently infected (PI) animals as primary sources of BVD viruses.
The cattle industry has a moral and ethical obligation not to sell known diseased or damaged animals to other parties without full disclosure. In support of the AVC BVD ad hoc committee's mission of BVD control we recognize that responsible disposition of animals persistently infected with BVD (PIs) will be an important component of BVD control.
The dilemma of how to deal with known PI cattle becomes more critical as BVD testing becomes more widespread. Appropriate disposition of known PI cattle must take into account the adverse impact those cattle have on health, welfare and the economic return of the other cattle or cattle operations they may expose to BVD.
It is widely recognized the PI animal is defective and once confirmed, their PI status should thereafter be disclosed as exposure to these cattle has health ramifications for all cattle, especially those intended for reproduction purposes. Therefore, marketing or movement of PI's in any matter that potentially exposes at risk cattle is strongly discouraged.
|
COMPOUNDING FOR FOOD PRODUCING ANIMALS
|
When products for cattle are compounded and not in
compliance with A.M.D.U.C.A.,CPG 608.400, and any other
applicable state or federal laws, the products are adulterated,
misbranded and unapproved. With these products, there
is no scientific evidence to support their efficacy,
safety for the treated animal, and residue avoidance.
Therefore, they are prohibited. Therefore, it is the
resolve of the Academy of Veterinary Consultants that
with the exception of certain antidotes and large volume
electrolyte products as stated in CPG 608.400, compounded
products should not be used in cattle.
Made Public 12/2009
|
JUDICIOUS THERAPEUTIC USE OF ANTIMICROBIALS IN CATTLE
|
AVC recognizes the importance of antimicriobial stewardship and has adopted the same stance as AABP on the topic.
Click HERE to read the guidelines (updated March 2024) |
|
|